Outcomes for children with chronic granulomatous disease (CGD) have histori
cally been poor, but significant improvements have occurred with the use of
effective antibacterial prophylaxis. The present study aimed to document t
he clinical course of a cohort of children diagnosed with CGD since 1990 in
a single centre. Twenty-one patients were identified, with a median age at
last assessment of 4 years and 5 months. A third of these children were di
agnosed in infancy because of a positive family history. Of the remaining,
there was a median delay between the onset of symptoms and diagnosis of 13
months. No invasive or fungal infections were documented after diagnosis, n
or were there any deaths in this cohort. A variety of non-infectious compli
cations were noted, which responded well to steroids. As a group, these chi
ldren were thriving and weight and height distributions fell within the pop
ulation norm. All patients were receiving antibacterial prophylaxis, 90% wi
th co-trimoxazole, and all but one patient were receiving a prophylactic an
ti-fungal agent (itraconazole). Both drugs were well tolerated. In conclusi
on, this cohort of patients, diagnosed in the last decade, tolerated antiba
cterial and anti-fungal prophylaxis well and on this regimen have a signifi
cantly decreased incidence of infection when compared with historical cohor
ts. Careful follow up of patients who have had aggressive antibacterial and
anti-fungal prophylaxis should continue. The data reported on this cohort
of patients should inform the debate about the use of more aggressive treat
ments, such as bone marrow transplantation, in this disease.